NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis

Eton Pharmaceuticals, Inc. (ETON) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ETON

$49.30

−$0.89 (−1.77%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ETON with… →

ETON Key Statistics

As of Oct 21, 2026
Trading
Open
$50.16
Previous Close
$50.19
Day's Range
48.71–50.81
52-Week Range
14.27–66.37
Volume
310.03K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.90
Valuation
Market Cap
$1.41B
P/E Ratio
123.25
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
19.33
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
13.34
EPS (ttm)Profit attributable to each share over the last twelve months.
0.40
Financials (FY)
Revenue (FY)
$79.95M+104.94%
Net Income (FY)
−$4.60M
Profit marginThe share of revenue left as profit after all costs and taxes.
12.02%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
28.58M
1-Year Return
+165.77%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
589.16K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ETON closed at $49.30, +165.77% over 1 year.

Eton Pharmaceuticals, Inc. (ETON) has a market capitalization of $1.41B.

In fiscal 2025, ETON reported revenue of $79.95M.

ETON Stock Return by Calendar Year

Eton Pharmaceuticals, Inc. (ETON) return since Nov 2018: what $10,000 became

1 year
$10,000 $26,577
+165.77%
5 years
$10,000 $88,669
+786.69%
Since Nov 2018
$10,000 $78,880
+688.80%

If you had invested $10,000 in Eton Pharmaceuticals, Inc. (ETON) at the close on November 13, 2018, the earliest close on record here, it would have been worth $78,880 at the close on October 21, 2026: +688.80% in total, +29.72% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+191.54%
2025+26.95%
2024+204.11%
2023+55.32%
2022−34.27%
2021−47.23%
2020+12.92%
2019+17.65%
2018 (partial year)−2.08%

As of October 21, 2026.

ETON Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$79.95M−$4.60M−5.8%
2024$39.01M−$3.82M−9.8%
2023$31.64M−$936.00K−3.0%
2022$21.25M−$9.02M−42.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$79.95M$42.74M−$844.00K−$4.60M−5.8%
2024$39.01M$23.41M−$2.60M−$3.82M−9.8%
2023$31.64M$21.06M−$1.19M−$936.00K−3.0%
2022$21.25M$14.32M−$8.26M−$9.02M−42.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ETON Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricETONDrug Manufacturers - Specialty & Generic medianvs median
P/E123.2520.316.1x the median
P/S ratio13.342.106.4x the median
Profit margin12.02%−8.14%20.2 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Eton Pharmaceuticals, Inc. (ETON) at $1.41B. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 44 employees.

The 52-week range on file runs from $14.27 to $66.37. The most recent close on file for ETON is $49.30, dated October 21, 2026. That is −$0.89 (−1.77%) against the previous close. The latest close sits 245.48% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $79.95M. Against the prior fiscal year total of $39.01M, that is a change of +104.94%. The same year closed with a net loss of $4.60M. Profit margin runs at 12.02%. That is 20.2 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to 0.4.

Across the 4 fiscal years on file, revenue moves from $21.25M in 2022 to $79.95M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

ETON trades at a trailing price-to-earnings ratio of 123.25. That is 6.1 times the Drug Manufacturers - Specialty & Generic median of 20.31. On forward earnings the ratio is 19.33. Measured against sales, the shares trade at 13.34 times revenue. On price-to-sales that is 6.4 times the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

Beta against the wider market is reported at 0.9. Daily returns over the trailing 7 years annualize to a volatility of 67.1%. Over the trailing twelve months the total return is +165.77%. Measured over 5 years, that is +54.72% a year compounded.

Growth & Income

No dividend is on file for ETON.

So far in 2026 the total return is +191.54%. Across the complete calendar years on file, 2024 returned +204.11% and 2021 returned −47.23%. Of the 7 complete calendar years on file, 5 finished higher.

Peer Comparison

Eton Pharmaceuticals, Inc. (ETON) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Eton Pharmaceuticals, Inc. ETON $1.41B 123.3
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Eton Pharmaceuticals, Inc. trades at a P/E of 123.3.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Visit website →